Home > Haematological Malignancies
    • FILTER YOUR SEARCH
    Content Type:

    • Haematological Malignancies

    An Introduction to Haematological Malignancies

    In recent years, advances in our understanding of the pathological mechanisms underlying haematological malignancies have led to improved outcomes. Several novel drug classes are now emerging, including chimeric antigen receptor (CAR) T-cell therapy, molecular targeted therapies, bispecific T-cell engaging antibodies, CD47 blockade therapy and antibody-drug conjugates. Many challenges remain, however, including how best to combine agents and determining where new therapies fit into the treatment paradigm.

    Expert video highlights, insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the changing treatment landscape. To learn more about how the latest developments impact on patient outcomes view our expert-led learning activities.”

    Our supporting partners do not constitute an endorsement of the content on this page.

    Haematological Malignancies Content

    Haematological Malignancies
    touchTALKS
    Exploring the changing landscape in Waldenström’s macroglobulinaemia: How will emerging BTK inhibitors alter patient outcomes?
    Dr Alessandra Tedeschi Watch Time: 39 Minutes

    Join Dr Alessandra Tedeschi as she highlights the latest data on second-generation Bruton’s tyrosine kinase inhibitors in the management of Waldenström’s macroglobulinaemia.

    Learning objectives
    Learning Objectives
    • Evaluate the new and emerging efficacy data for second-generation BTK inhibitors in patients with WM
    • Summarize the adverse events associated with second-generation BTK inhibitors
    • Review current management recommendations for people with Waldenström’s macroglobulinaemia
    Multiple Myeloma
    Melflufen—A Novel Agent in the Treatment of Relapsed/Refractory Multiple Myeloma
    Paul G Richardson

    Oncology & Hematology Review (US). 2020; 16(1):12–4 DOI: https://doi.org/10.17925/OHR.2020.16.1.12

    Multiple myeloma (MM) is the second most common hematological malignancy after non-Hodgkin’s lymphoma.1 Although recent decades have seen considerable advances and improvements in clinical outcomes for patients with MM,2 MM remains incurable, with a high disease burden.3 Clonal evolution and genomic instability within myeloma clones inevitably lead to disease progression and treatment resistance.4 An increasing number […]

    Multiple Myeloma
    touchPANEL DISCUSSION
    Current management of relapsed/refractory multiple myeloma and the future integration of BCMA-targeting agents
    CME ACCREDITED Dr Rakesh Popas, Dr Paula Rodríguez-Otero, Prof. Katja Weisel Watch Time: 31 mins

    Watch a panel of internationally renowned multiple myeloma experts discuss the management of relapsed/refractory disease and the future for B-cell maturation antigen (BCMA)-targeted agents

    Learning objectives
    Learning Objectives
    • Discuss how treatment for patients with relapsed/refractory multiple myeloma can be selected based on disease- and patient-related factors
    • Describe the rationale for B-cell maturation antigen (BCMA) as a treatment target and current agents in development
    • Recall the latest data for BCMA-targeting agents in relapsed/refractory multiple myeloma and consider how they may be incorporated into clinical practice
    Lymphoma
    touchPANEL DISCUSSION
    CAR-T in clinical practice: Navigating the patient journey from referral to long-term follow-up
    CME ACCREDITED Prof. Mohamad Mohty, Dr John Kuruvilla, Dr Robin Sanderson Watch Time: 32 mins

    Get an update on CAR-T therapy in clinical practice with this expert discussion on real-world data, patient referral and the important collaboration between referral and treatment centres.

    Learning objectives
    Learning Objectives
    • Recall the latest real-world evidence for the use of chimeric antigen receptor T-cell (CAR-T) therapy in patients with diffuse large B-cell lymphoma (DLBCL)
    • Describe which patients with DLBCL should be referred for assessment for CAR-T therapy and discuss the importance of early referral
    • Discuss the roles of referral centres and treatment centres in patient management, in particular long-term follow up of patients
    Multiple Myeloma
    touchCONGRESS
    BMCA-targeting agents in relapsed/refractory multiple myeloma: Distilling the data from the ASCO Annual Meeting 2020
    CME ACCREDITED Prof. Kwee Yong, Prof. Mohamad Mohty, Prof. Pieter Sonneveld Watch Time: 72 mins

    Find out about the latest data on the use of B-cell maturation antigen (BCMA)-targeted therapies in the management of relapsed/refractory multiple myeloma through our touchCONGRESS Webinar and Expert Interviews with European experts discussing data from ASCO20 Virtual.

    Learning objectives
    Learning Objectives
    • Discuss the need for new treatment options for relapsed/refractory multiple myeloma and the rationale for targeting B-cell maturation antigen (BCMA)
    • Describe the latest efficacy data for BCMA-targeting agents and evaluate how they may be integrated into the current treatment pathway
    • Describe the latest safety data for BCMA-targeting agents and consider how adverse events could be managed in clinical practice
    Multiple Myeloma
    touchEXPERT OPINIONS
    Biomarkers and novel therapies in relapsed/refractory multiple myeloma: Where are we heading in 2020?
    CME ACCREDITED Prof. Graham Jackson Watch Time: 28 Mins

    Watch leading expert Prof. Graham Jackson discuss the importance of identifying high-risk patients with relapsed/refractory multiple myeloma and the role of biomarkers and novel therapies in optimizing individual patient care.

    Learning objectives
    Learning Objectives
    • Identify those patients with relapsed/refractory multiple myeloma with the most significant unmet needs
    • Describe existing and novel biomarker testing and the relevance for optimizing the treatment of relapsed/refractory multiple myeloma
    • Discuss the evidence for novel treatments and the potential for further treatment optimization with combination treatments in clinical trials and practice
    Multiple Myeloma
    Shaji Kumar, ASCO20: Efficacy and Toxicity in the Randomised Phase III ENDURANCE Trial in Myeloma

    We are joined by touchONCOLOGY’s Oncology & Hematology Review (US) Editor-in-Chief Shaji Kumar, Mayo Clinic, to discuss his plenary session at ASCO20 on the efficacy and toxicity in the randomized phase III ENDURANCE trial of the use of bortezomib, lenalidomide and dexamethasone for initial therapy of newly diagnosed multiple myeloma. Questions 1. What is the […]

    Haematological Malignancies
    touchPANEL DISCUSSION
    Have the next generation of BTK inhibitors come of age for the treatment of Waldenström’s macroglobulinemia?
    Dr Roger Owen, Prof. Veronique LeBlond, Prof. Christian Buske Watch Time: 38 Mins

    Watch a panel of internationally renowned Waldenström’s macroglobulinemia experts discuss the clinical utility of second-generation Bruton’s tyrosine kinase (BTK) inhibitors, and their potential impact on the current treatment paradigm.

    Learning objectives
    Learning Objectives
    • Identify the pharmacokinetic and pharmacodynamic attributes of second-generation BTK inhibitors
    • Discuss emerging clinical data with second-generation BTK inhibitors in Waldenström’s macroglobulinemia (WM)
    • Discuss the potential of second-generation agents to improve patients’ outcomes and experiences in WM
    Leukaemia
    Role of New Immunophenotypic Markers on Prognostic and Overall Survival of Acute Lymphoblastic Leukaemia – A Systematic Review and Meta-analysis
    Wesley Messias Santos, Amanda Fernandes Oliveira Costa, Lucio Henrique Sousa Pinheiro

    European Oncology & Haematology. 2019;15(2):113–20

    Acute lymphoblastic leukaemia (ALL) is a group of malignant haematological disorders characterised by accumulation of lymphoid cell precursors that replace normal bone marrow elements and inhibit the production of functional blood cells.1 ALL occurs in both children and adults, and more than one-half (56%) of those diagnosed are <20 years old, with chemotherapy required as standard […]

    Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-blueavatarcalendarchevron-down crosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmenumore_dots padlock person play_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar